Medication info
Neuronal Gabapentin Capsule 75 mg (Pregabalin)

Neuronal Gabapentin Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
Hard capsules with a reddish brown upper part and a white lower part containing a white or light yellow powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201502966 · Approved 2015.05.18 · Insurance code 622802460

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, pregabalin, orally in 2 divided doses, with or without food. This medicine is excreted mainly by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg per day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg per day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg per day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is excreted mainly by the kidneys as unchanged drug after entering the systemic circulation. Because the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the dosage regimen. b: A supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Use is not recommended in children under 12 years of age or adolescent patients aged 12 ~17 years because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunctive medication for partial seizures in epilepsy patients, applicable in cases with or without secondary generalized symptoms. Additionally, it helps alleviate symptoms in patients with fibromyalgia. This medication is used for a range of neurological disorders and pain symptoms, improving the quality of life for patients.

How to take

Adult dose

Administer the total daily dose of this medicine, pregabalin, orally in 2 divided doses, with or without food. This medicine is excreted mainly by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg per day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg per day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg per day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is excreted mainly by the kidneys as unchanged drug after entering the systemic circulation. Because the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the dosage regimen. b: A supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Use is not recommended in children under 12 years of age or adolescent patients aged 12 ~17 years because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or actions, so mood or behavior changes should be closely monitored during treatment. Patients with hypersensitivity to this medication or certain genetic disorders such as lactose intolerance should not take it. Diabetic patients should be cautious as weight gain may affect blood glucose control. If symptoms of angioedema occur, medication should be stopped immediately. Elderly patients should be careful about the risk of falling due to dizziness or drowsiness. Visual disturbances or changes in vision may occur during treatment, so if any unusual symptoms arise, consult a healthcare professional. Withdrawal symptoms such as insomnia, headaches, or anxiety may occur upon discontinuation of the medication, so abrupt cessation should be avoided and follow healthcare provider instructions. Due to the risk of drug abuse, patients with a history of substance abuse should use this medication more cautiously. Patients with heart disease or severe congestive heart failure require special attention when taking this medication. When taken with opioid analgesics, the risk of central nervous system depression increases, so caution is advised when used together. Patients with respiratory diseases, renal impairment, or elderly individuals may require dose adjustments due to severe respiratory depression risks. Pregnant women should avoid using this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing age should ensure effective contraception. Breastfeeding women should consider discontinuing either breastfeeding or the medication as it can be transmitted through breast milk. Before driving or operating hazardous machinery, check for dizziness or drowsiness due to this medication for safety. Serious skin reactions such as Stevens-Johnson syndrome may occur, so if any skin abnormalities appear, discontinue use immediately and consult a healthcare professional. In case of overdose, symptoms such as confusion, drowsiness, or seizures may occur, requiring immediate medical attention for appropriate treatment. This medication should be kept out of the reach of children, and care should be taken to avoid transferring it to other containers, which may cause accidents.

Side effects

  • suicidal impulses
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 182 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • sadness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • weight gain
  • rhinosinusitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual dysesthesia
  • agitation
  • mood swings
  • emotional lows
  • emotional highs
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • dyscoordination
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • trembling
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • hypersomnolence
  • cognitive impairments
  • nystagmus
  • speech disorders
  • myoclonic jerks
  • reflex reduction
  • movement disorders
  • psychomotor agitation
  • postural dizziness
  • hyperesthesia
  • burning sensation
  • tremor
  • syncope
  • confusion
  • hypomobility
  • olfactory disturbances
  • loss of taste
  • writing disorder
  • diplopia
  • vertigo
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • sialorrhea
  • gastroesophageal reflux disease
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • diaphoresis
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • swelling
  • abnormal gait
  • falls
  • feeling intoxicated
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased potassium levels
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • mood disorders
  • drowsiness
  • confusional state
  • agitation
  • restlessness
  • seizures
  • mood disorders
  • drowsiness
  • confusional state
  • depression
  • agitation
  • restlessness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to maintain a storage temperature between 15 degrees and 30 degrees Celsius. This will help maintain the medication's effectiveness and safety.

Appearance and packaging

Appearance

Hard capsules with a reddish brown upper part and a white lower part containing a white or light yellow powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.